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Abstract
Objectives: Recent improvements in surgical technique have extended the indications for liver resec-
tion. The aims of this study were to assess whether this extension is associated with a changing patient
profile and to evaluate how this potential shift has influenced mortality after liver resection in order to
define standard expectations for hepatectomy.
Methods: The characteristics and postoperative outcomes of all patients undergoing elective hepate-
ctomy from 2000 to 2009 were reviewed retrospectively. Multivariate analysis was conducted to deter-
mine the factors associated with mortality in the subgroup of patients with malignant disease.
Results: Among the 2012 patients in whom hepatectomies were performed, the percentage of patients
operated for malignancy increased from 66.4% in 2000 to 82.3% in 2009 (P < 0.001). These patients
experienced higher mortality (4.5% versus 0.7%; P < 0.001), were significantly older, and displayed
greater comorbidity and underlying parenchymal disease compared with those with benign lesions.
Mortality over the entire study period was 3.5% and was fairly stable, dropping from 3.8% in 2000 to 3.1%
in 2009 (P = 0.686). On multivariate analysis, age of >60 years, an American Society of Anesthesiologists
score of 3, major resection, vascular procedure, severe fibrosis (F3–F4) and steatosis of >30% were
associated with increased mortality in patients with malignant disease.
Conclusions: The profile of patients undergoing liver resection has changed and now includes more
high-risk patients with diseased parenchyma undergoing major hepatectomy for malignancy. This change
in patient profile is responsible for the stability in mortality rates over the years.
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Introduction
During the last decades of the 20th century, several factors con-
tributed to reduce mortality after hepatectomy from 5% to almost
0%.1–4 Among these factors, better knowledge of both liver
anatomy and physiology, including of liver regeneration and
preoperative volume modulation,5 better morphological assess-
ment,6 advances in parenchymal transection with the selective use
of vascular control7 and sophisticated perioperative management
have all contributed to reduce the risks associated with liver resec-
tion. Although better characterization of liver lesions prevents the
unnecessary resection of benign lesions, the number of hepatec-
tomies carried out for malignancy is increasing. For example, both
screening in high-risk individuals with viral hepatitis or metabolic
syndrome, and more efficient chemotherapy regimens currently
allow resection in increasing numbers of patients with hepatocel-
lular carcinoma (HCC) and colorectal liver metastasis (CLM).
However, such patients are more likely to demonstrate pathologi-
cal changes in the underlying parenchyma, such as fibrosis, stea-
tosis and chemotherapy-associated liver injury.8–10 It is therefore
likely that such parenchymal changes, along with modifications in
patient characteristics, may impede anticipated improvements in
results after liver resection.11,12 Hence, the aims of the current
study were to assess changes in both the profile of patients under-
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going hepatectomy and factors predictive of mortality in these
patients in a single tertiary care centre over a 10-year period in
order to define standard expectations in hepatectomy.
Materials and methods
All patients who underwent elective liver resections between
January 2000 and December 2009 at Beaujon Hospital, Clichy,
France, were included. During the study period, 2012 elective hepa-
tectomies were performed in 1958 patients. Data for this 10-year
period were collected prospectively and analysed retrospectively.
Patients who underwent resection after liver transplantation, biliary
cyst fenestration or excisional biopsy were excluded. To assess a
possible change in the patient profile and its influence on the evo-
lution in mortality rates over time, the 2000–2009 study period was
arbitrarily divided into two periods of equal duration (2000–2004
and 2005–2009) and data for the 1990s were extracted from analy-
ses previously reported by the present group.13 Accordingly, several
parameters, including preoperative characteristics (age >60 years,
existence of an associated medical comorbidity), indication for liver
resection (benign versus malignant disease), extent of resection and
mortality rate were compared across these different periods.
Preoperative management
Standard preoperative workup included blood analysis with liver
tests and imaging by computed tomography or magnetic resonance
imaging in all patients. Tumour and parenchymal biopsies were
performed selectively. Preoperative portal vein embolization (PVE)
(n = 120) prior to right or extended right hepatectomy was under-
taken when the anticipated future liver remnant was <25% of liver
size in patients with strictly normal liver and <35–40% in patients
with underlying liver disease.5 Preoperative PVE was preceded by
transarterial chemoembolization in 36 HCC patients. No patients
with cirrhosis of Child–Pugh classes B or C underwent surgery.
Among 546 (27.1%) patients operated for CLM, 401 (73.4%)
received neoadjuvant chemotherapy. Preoperative endoscopic or
percutaneous biliary drainage was performed in 53 (2.6%) jaun-
diced patients with biliary tumours involving the confluence in
order to achieve a preoperative bilirubin level of <50 mmol/l.
Operative procedure
Intraoperative assessment with conventional B-mode sonography,
parenchymal transection and haemostasis was performed as previ-
ously described.13 However, since 2000, several techniques that were
not commonly used during this group’s previously reported expe-
rience, such as the laparoscopic approach and the hanging manoeu-
vre,14 were performed in 93 (4.6%) and 719 (66.5% of all major
resections) patients, respectively. From 2000, only 44 patients
(2.2%) were operated through thoracoabdominal incisions. The
routine use of Doppler sonography greatly facilitated surgery in
cases of extensive hepatectomy with involvement of the portal vein,
major hepatic veins, vena cava or hepatic artery requiring vascular
reconstruction. Major extrahepatic resections were undertaken in
257 patients (12.8%); these included colonic resections in 120
patients, pancreas or duodenum resections in 50 patients, stomach
resections in 17 patients and other types of resections in the remain-
ing 70 patients. Major resection was defined as the resection of three
or more adjacent segments. Intraoperative variables analysed
included operative time, estimated blood loss, transfusion require-
ments, duration of vascular clamping, extent of resection, and asso-
ciated liver (vascular or biliary) and extrahepatic procedures.
Histological analysis
In addition to tumour characteristics, the underlying liver paren-
chyma was assessed for the existence of fibrosis graded from F0 to
F4.15 Fibrosis of stages F3 and F4 was considered severe. Steatosis
of >30% based on the percentage of hepatocytes with fat droplets
was considered significant. In patients with CLM who received
preoperative chemotherapy, chemotherapy-induced liver injury
was considered significant if it resulted in chemotherapy-
associated steatohepatitis (CASH)10 and/or sinusoidal obstruction
syndrome (SOS) including lesions of grades 2 or 3 8,9 and nodular
regenerative hyperplasia.16
Postoperative care
Postoperative complications were stratified according to the
Clavien–Dindo classification.17 Major complications (Clavien–
Dindo classes 3 and 4) and operative mortality (Clavien–Dindo
class 5) were considered when they occurred within 90 days after
surgery or at any time during postoperative hospitalization. Spe-
cific liver complications that frequently develop after major liver
surgery were described as follows: (i) liver failure was defined
according to the ‘50-50 criteria’ on postoperative day 5 as previ-
ously reported;18 (ii) ascites was defined as >10 ml/kg/day of drain-
age output from the abdomen after postoperative day 5,19 and (iii)
bile leakage was defined as a bilirubin concentration in the drain
fluid at least three times that of serum bilirubin on or after post-
operative day 3 or as the need for radiological or operative inter-
vention resulting from biliary collections or bile peritonitis.20 In the
majority of patients, the diagnosis of biliary fistula was first sus-
pected macroscopically and subsequently confirmed biologically.
Statistical analysis
Continuous variables are expressed as mean values with ranges
and were compared using the Mann–Whitney U-test. Categorical
variables were compared using the chi-squared test with Yates’
correction or Fisher’s exact test as appropriate. Univariate analysis
was used to examine the relationships between mortality and
several clinical, operative and pathological parameters. All vari-
ables achieving statistical significance at a level of 0.1 in the
univariate analysis for predictive factors for mortality were
considered for multivariate analysis. A backward variable proce-
dure with a P-value cut-off of 0.05 was used to identify independ-
ent factors predictive of mortality in the whole group with
malignant disease, as well as in the three subgroups of patients
with HCC, CLM and biliary tumours, respectively. All statistical
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tests were two-sided. For all tests, statistical significance was
defined by a P-value of <0.05. Data were analysed using spss
Version 18.0 for Windows (SPSS, Inc., Chicago, IL, USA).
Results
Indications for the 2012 elective hepatectomies performed during
the study period are summarized in Table 1. The vast majority
(72.2%) of liver resections were performed for malignant lesions, of
which CLM represented the most common. Liver cell adenoma was
the most frequently operated benign lesion. Whereas the overall
number of hepatectomies remained stable during the study period,
the rate of resection for benign disease significantly declined from
33.5% (61 of 182) in 2000 to 17.8% (40 of 225) in 2009 (P < 0.001).
Patient characteristics
The mean age of patients was 54.4 years (range: 14–85 years) and
44.0% of patients displayed at least one associated medical comor-
bidity. As Table 2 shows, the comparison of preoperative variables
between patients with malignant and benign disease, respectively,
revealed that patients with malignancy were significantly older
and displayed greater comorbidity, including metabolic factors.
An abnormal underlying parenchyma was more frequently
observed in patients with malignant lesions than in those
with benign lesions. Specifically, severe fibrosis and significant
chemotherapy-associated liver injury were present in 62.0% and
35.0% of HCC and CLM patients, respectively.
Table 1 Indications for liver resection in 2012 patients
Indication n (%)
Malignant (n = 1453)
Primary tumours 701 (48.2%)
Hepatocellular carcinoma 450 (30.9%)
Biliary tumours 194 (13.4%)
Intrahepatic carcinoma 81 (5.6%)
Hilar carcinoma 78 (5.4%)
Gallbladder carcinoma 35 (2.4%)
Others 57 (3.9%)
Secondary tumours 752 (51.8%)
Colorectal metastases 546 (37.6%)
Neuroendocrine metastases 115 (7.9%)
Other metastases 91 (6.3%)
Benign (n = 559)
Adenoma 129 (23.1%)
Focal nodular hyperplasia 61 (10.9%)
Haemangioma 32 (5.7%)
Hydatid and cystic disease 77 (13.8%)
Polycystic liver disease 40 (7.2%)
Living donor transplant 93 (16.6%)
Hepatolithiasis 32 (5.7%)
Others 95 (16.9%)
Table 2 Preoperative characteristics
Malignant disease group
(n = 1453)
Benign disease group
(n = 559)
P-value
Age, years, mean (range) 58.7 (14–85) 42.8 (15–84) <0.001
Age >60 years, n (%) 735 (50.6%) 80 (14.3%) <0.001
Female gender, n (%) 533 (36.7%) 372 (66.5%) <0.001
BMI, kg/m2, mean (range) 25.2 (14.6–45.4) 24.2 (14.3–48.9) <0.001
BMI of >30 kg/m2, n (%) 215 (14.8%) 65 (11.6%) 0.065
Comorbidity, n (%) 728 (50.1%) 157 (28.1%) <0.001
Diabetes 220 (15.1%) 24 (4.3%) <0.001
Hypertension 470 (32.3%) 78 (13.9%) <0.001
Cardiac disease 148 (10.2%) 22 (3.9%) <0.001
Pulmonary disease 156 (10.9%) 36 (6.4%) 0.003
ASA class 3, n (%) 103 (7.1%) 10 (1.8%) <0.001
Underlying parenchyma, n (%)
Normal 525 (36.1%) 328 (58.7%) <0.001
Steatosis of >30% 189 (13.1%) 44 (7.9%) 0.001
Fibrosis of F1/F2 454 (31.3%) 128 (22.9%) <0.001
Fibrosis of F3/F4 362 (24.9%) 41 (7.3%) <0.001
Chemotherapy-induced injurya, n (%) 249 (66.9%) 0 –
aChemotherapy-induced liver injury was only observed in the group with colorectal liver metastases.
BMI, body mass index; ASA, American Society of Anesthesiologists.
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Surgical procedures
Intraoperative data for the entire series are summarized in Table 3.
Patients with malignant disease underwent more complex resec-
tions with higher rates of associated vascular, biliary and extrahe-
patic procedures, longer operative times and increased blood loss,
and more frequently required transfusion as well as longer vascu-
lar occlusion. Major hepatectomy was performed in 1084 (53.9%)
patients and included right or extended right hepatectomy in 696
(34.6%) cases. Although the rates of major hepatectomy were
similar in the groups with benign and malignant disease, patients
with malignant disease who underwent major resection had
increased blood loss (883.6 ml versus 774.6 ml; P < 0.001) and
more often required vascular occlusion (77.4% versus 63.2%; P <
0.001) compared with those undergoing major resection for
benign disease. Of the 205 patients with malignant disease who
required extrahepatic procedures, 80 patients with CLM under-
went concomitant colonic resection. Of these, only 16 (20.0%)
procedures were performed along with major hepatectomy.
Among the 152 (10.5%) patients with malignant disease who
required vascular reconstruction, 38 (25.0%) had biliary cancer,
56 (36.8%) had CLM, 34 (22.4%) had HCC and the remaining 24
(15.8%) had other types of hepatic malignancies. Almost 20% of
the 194 patients with biliary cancer required vascular reconstruc-
tion involving the portal vein (n = 33), hepatic veins or inferior
vena cava (n = 12) and/or the hepatic artery (n = 7).
Perioperative course
As Table 4 shows, 1134 (56.4%) patients experienced postoperative
complications, including 420 (20.9%) of Clavien–Dindo class 3 or 4.
Pulmonary complications were noted in 408 (20.3%) patients. Spe-
cific post-hepatectomy complications included ascites in 418
(20.8%), abdominal collection requiring drainage in 167 (8.3%),
biliary fistula in 152 (7.6%) and liver failure in 41 (2.0%) patients.
Among the 100 (5.0%) patients requiring reoperation,26 underwent
laparotomy for haemorrhage. The incidence of perioperative com-
plications was significantly lower in the group with benign disease, in
whom both intensive care unit and overall hospital stays were lower
than in the malignant disease group. Specifically, in the malignant
disease group, the incidence of major complications was 41.8% in
the subgroup of patients with biliary malignancy, compared with
26.8% and 22.7% in patients who underwent liver resection for HCC
or CLM, respectively (both P < 0.05). There were 70 postoperative
deaths, giving overall perioperative mortality of 3.5%. Mortality was
significantly lower in patients undergoing surgery for benign lesions
compared with those with malignant disease (P < 0.001).
Patient-related factors associated with mortality
Four (0.7%) postoperative deaths were observed in the 559 patients
operated for benign conditions. These deaths occurred in three
patients who underwent major hepatectomy for hepatolithiasis
and who succumbed to uncontrollable sepsis, and in one living
donor after right hepatectomy, who was found to have previously
undiagnosed myeloma.21 Overall mortality in patients with malig-
nant disease was 4.5%. A subgroup analysis revealed a difference in
mortality rates between distinct aetiologies: patients with CLM had
a mortality rate of only 1.7%, which was significantly lower than
the 6.4% rate in HCC patients (P < 0.001) and the 8.2% rate in
patients with biliary tumours (P < 0.001). Multiple preoperative,
operative and histological variables were associated with increased
risk for mortality in univariate analysis (Table 5). The univariate
analysis showed significance for male sex, age >60 years, existence
of associated comorbidity, American Society of Anesthesiologists
(ASA) score of 3, major resection, transfusion, blood loss of
>1000 ml, vascular clamping, associated vascular or bile duct pro-
Table 3 Intraoperative characteristics
Benign disease
group
(n = 559)
Malignant disease group
Overall
(n = 1453)
HCC
(n = 450)
CLM
(n = 546)
Biliary tumours
(n = 194)
Major hepatectomy, n (%) 299 (53.5%) 783 (53.9%) 206 (45.8%)a,b 284 (52.1%)c 151 (77.8%)
Associated procedures, n (%) 60 (10.8%)d 399 (27.5%) 52 (11.6%)a,b 141 (25.9%)c 113 (58.2%)
Extrahepatic 16 (2.7%)d 205 (14.1%) 19 (4.2%)a,b 94 (17.2%)c 20 (10.3%)
Vascular 9 (1.6%)d 153 (10.5%) 34 (7.6%)b 56 (10.3%)c 38 (19.6%)
Biliary 40 (7.2%) 128 (8.8%) 6 (1.3%)b 12 (2.2%)c 103 (53.1%)
Operative time, min, mean (range) 306.55 (30–942)d 325.18 (20–765) 285.14 (60–765)a,b 323.93 (20–690)c 425 (160–755)
Estimated blood loss, ml, mean (range) 525.21 (0–13000)d 633 (14–11000) 681.27 (0–11000) 607.89 (0–6000) 698.17 (0–3500)
Transfusion, n (%) 86 (15.3%)d 330 (22.7%) 91 (20.2%)b 114 (20.9%)c 61 (31.4%)
Pedicle clamping, n (%) 281 (50.3%)d 930 (64.0%) 290 (64.4%)b 347 (63.5%)c 141 (72.7%)
Duration, min, mean (range) 37.4 (0–212)d 42.2 (5–150) 42.8 (1–150) 40.8 (3–148) 43.4 (7–140)
aMarks a significant difference between HCC and CLM.
bMarks a significant difference between HCC and biliary tumours.
cMarks a significant difference between CLM and biliary tumours.
dMarks a significant difference between the benign and malignant disease groups.
HCC, hepatocellular carcinoma; CLM, colorectal liver metastasis.
HPB 911
HPB 2013, 15, 908–915 © 2013 International Hepato-Pancreato-Biliary Association
cedures, presence of severe fibrosis, steatosis of >30% and
chemotherapy-induced liver injury in patients operated for CLM
(P< 0.001).Within the study period, neither the 2000–2004 nor the
2005–2009 time interval proved to be a risk factor for mortality in
univariate analysis (P = 0.261). In multivariate analysis (Table 5),
common risk factors for mortality for all three types of malignancy
were age >60 years, ASA score of 3, need for inflow clamping,
increased blood loss, transfusion and steatosis of >30%. In patients
with CLM, the presence of chemotherapy-induced liver injury
[odds ratio (OR) 2.568, 95% confidence interval (CI) 1.312–9.467;
P = 0.003] and need for associated vascular (OR = 10.048, 95% CI
5.26–18.371; P = 0.03) or biliary (OR = 13.125, 95% CI 2.488–
69.795; P = 0.018) procedures were independent risk factors for
mortality. In the subgroup of HCC patients, mortality was also
increased in patients undergoing major resection and with under-
lying liver fibrosis of F3–F4 (OR = 4.101, 95% CI 1.402–11.997;P =
0.006), whereas in patients with biliary malignancy, mortality was
also increased by an associated vascular procedure (OR = 11.116,
95% CI 2.083–19.332; P = 0.005).
Relationship between evolution in the profile of liver
resection patients and mortality
As Fig. 1 shows, rates of patients aged >60 years, patients with
medical comorbidities, patients undergoing resection for malig-
Table 4 Postoperative outcomes
Benign disease
group
(n = 559)
Malignant
disease group
(n = 1453)
CLM
(n = 546)
HCC
(n = 450)
Biliary tumours
(n = 194)
Mortality, n (%) 39 (50.7%)a 65 (4.5%) 9 (1.7%)b 29 (6.4%) 16 (8.2%)d
Overall morbidity, n (%) 267 (47.7%)a 870 (59.9%) 286 (52.3%)b 927 (63.8%)c 146 (75.3%)d
Clavien–Dindo class 3, n (%) 97 (17.4%)a 392 (27%) 124 (22.7%) 121 (26.8%)c 81 (41.8%)d
Liver-specific complications, n (%)
Pulmonary 96 (17.1%)a 120 (21.5%) 100 (18.4%) 98 (21.8%) 54 (27.8%)d
Liver failure 22 (0.4%)a 39 (2.7%) 13 (2.4%) 9 (2.0%)c 10 (5.2%)d
Ascites 69 (12.4%)a 135 (24.1%) 98 (18%)b 131 (29.1%) 67 (34.5%)d
Biliary fistula 39 (7.0%) 113 (7.8%) 112 (7.7%) 28 (6.2%)c 27 (13.9%)d
Reoperation, n (%) 16 (2.9%) 84 (5.8%) 51 (3.5%)b 31 (6.9%) 16 (8.2%)d
Intensive care unit stay, days, mean (range) 3.9 (1–52)a 6.1 (1–67) 5.5 (1–62) 6.4 (1–57) 7.4 (1–67)d
Hospital stay, days, mean (range) 11.3 (1–90)a 14.6 (1–96) 13.4 (1–82) 14.2 (3–84)c 19.5 (2–81)d
aMarks a significant difference between the benign and malignant disease groups.
bMarks a significant difference between CLM and HCC.
cMarks a significant between HCC and biliary malignancy.
dMarks a significant difference between biliary malignancy and CLM.
HCC, hepatocellular carcinoma; CLM, colorectal liver metastasis.
Table 5 Univariate and multivariable analysis for mortality in patients with malignant disease
Malignant disease group
n (%) P-value (UV) OR 95% CI P-value (MV)
Male 52 (5.7%) 0.008 – – NS
Age >60 years 40 (5.4%) 0.096 1.530 1.123–2.534 0.036
ASA class 3 11 (9.7%) <0.001 3.003 1.515–5.952 0.017
BMI > 30 kg/m2 14 (6.5%) 0.069 – – NS
Blood loss >1000 ml 26 (10.6%) <0.001 3.963 2.315–6.783 <0.001
Transfusion 44 (13.3%) <0.001 7.692 4.538–13.043 <0.001
Major resection 53 (6.8%) <0.001 3.664 1.979–6.781 0.008
Vascular procedure 24 (15.6%) <0.001 5.559 3.262–9.746 <0.001
Bile duct resection 15 (11.7%) <0.001 – – NS
Fibrosis F3–F4 35 (9.6%) <0.001 3.511 2.131–5.785 <0.001
Steatosis >30% 16 (8.5%) 0.005 2.273 1.257–4.111 <0.001
Vascular occlusion 57 (6.1%) <0.001 3.697 1.815–7.530 <0.001
UV, univariate analysis; OR, odds ratio; 95% CI, 95% confidence interval; MV, multivariate analysis; NS, not significant; ASA, American Society of
Anesthesiologists; BMI, body mass index.
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nant disease, patients undergoing major hepatectomy and patients
displaying a diseased underlying parenchyma linearly increased
over the study periods. Mortality rates did not differ significantly
within the study period (3.8% in 2000–2004 versus 3.1% in 2005–
2009; P = 0.334), nor between this centre’s previously reported
experience in the 1990s (4.4%)13 and the overall rate during 2000–
2009 (3.5%) (P = 0.247).
Discussion
The current study demonstrates that the extending of indications
for liver resection has led to a linear increase in the rate of elderly
patients displaying associated comorbidity and undergoing major
resection for malignant lesions on diseased parenchyma. The
present results furthermore emphasize that these changes in the
patient profile are associated with the stabilizing of mortality
within the study period and in comparison with data previously
reported from this centre.13
In the present series, both the mortality rate of <1% and the
severe morbidity rate of <20% observed in the 559 patients under-
going liver resection for benign conditions meet the expected
targets of high-volume hepatopancreatobiliary units. Although
most patients with benign lesions were younger, displayed less
comorbidity and generally underwent liver resection with a
normal hepatic parenchyma, more than half of them underwent
major resections. This clearly illustrates that the improvements in
postoperative outcomes following liver resection represent the
consequence of refinements in both surgical technique and peri-
operative management.1–4 In this context, some authors have
emphasized the benefits of laparoscopy and encourage its use.22
The present series included only a limited laparoscopic experi-
ence, which mainly concerned highly selected patients with
benign lesions in normal parenchyma. This does not allow the
drawing of any conclusions on the use of laparoscopic hepatec-
tomy, not least because indications for the resection of benign
liver lesions continue to decrease. Undoubtedly, both more precise
preoperative diagnosis and better knowledge of the natural
history of benign lesions have led to a decrease in the rate of liver
resection for benign liver tumours, including adenoma, for which
resection is now indicated only in patients with a specific immu-
nohistochemical profile or with lesions of >5 cm in size.23 A
similar trend was observed in living donor liver transplantation, in
which both specific and persistent risks associated with major
resection are likely to explain the decreasing use of this strategy as
long as cadaveric grafts are available.24,25 In addition to one post-
operative death observed in a living donor,21 three deaths occurred
after major resection in patients with hepatolithiasis, a disease
characterized by both chronic liver infection and abnormal
underlying parenchyma.
In the present series, the risk for mortality was six-fold higher in
patients operated for malignant disease than in those undergoing
liver resection for benign lesions. This result was related to the
combination of several known factors, including patients’ comor-
bidity and underlying liver status, as well as some technical param-
eters. Although the influence of advanced age per se on the
postoperative course after liver resection is still under debate,26–28
the current study confirms the impact of the increase in the inci-
dence of associated medical comorbidity in parallel with increasing
age on both mortality and morbidity rates in patients with malig-
nant disease. One explanation for this is that these patients dis-
played significantly more metabolic risk factors, including
diabetes, hypertension and dyslipidaemia. It is likely that the exist-
ence of such risk factors was responsible for a higher rate of
underlying cardiorespiratory disease that led to the occurrence of
more cardiorespiratory events.29–31 However, it is obvious that the
metabolic syndrome itself accounted for increases in both under-
lying significant steatosis and steatohepatitis, which are now
known to directly or indirectly adversely affect the postoperative
course.32–34 Another explanation is that the very nature of the
malignancy is associated with several pathological changes in the
underlying liver, as was found in more than sixty percent of patients
in the present series. It is indeed well known that most HCC lesions
develop on diseased underlying parenchyma, including paren-
chyma with severe fibrosis and/or massive fatty infiltration,35–37 and
that the widespread use of chemotherapy in patients with CLM is
associated with an increasing rate of chemotherapy-associated liver
injury, including SOS8,9 and CASH.10 In the current study, as in
others,9,10,35–37 these underlying conditions were independent sig-
nificant risk factors for postoperative mortality. The last plausible
explanation is that the extending of indications for liver resection
in patients with malignancy has resulted in the performance of
more extensive and complex resections. In the present series, both
major liver resection and associated vascular procedures were per-
formed more frequently than in this centre’s previously reported
experience.13 This finding is likely to account for the fact that the
oncological rules require an anatomic resection38–40 and it is there-
fore unlikely that rates of major liver resection in patients with
HCC and biliary tumours will decrease. Nevertheless, despite a low
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rate of postoperative liver failure in the group of patients with
malignant disease, major liver resection in patients with abnormal
underlying parenchyma associated with vascular reconstruction
yielded a dramatically high mortality rate.41 In such situations, a
fine balance between caution and the necessary radical surgery
should be sought, as in patients with initially unresectable CLM.42
This study has several limitations as a result of its retrospective
nature. Although all resected patients were categorized as having
Child–Pugh class A disease, no correlation between the accurate
assessment of liver function and postoperative outcome could be
demonstrated. Platelet counts,18,43,44 as well as indocyanine green
(ICG) clearance3,4,45 are often used to estimate the risk for postop-
erative liver failure and early death. However, these tests may not
adequately distinguish between cirrhosis and lesser forms of
pathological changes45 and may therefore preclude resection in
otherwise suitable candidates. Another drawback refers to the
inability to determine the existence of features of non-alcoholic
steatohepatitis (NASH) in the underlying liver in all of the patients
in the present series. This series covers a 10-year period, at the
beginning of which NASH was not routinely assessed.Several series
have recently emphasized the negative impact of NASH on the
postoperative course34,35 and it is likely that, given the influence of
massive steatosis found in the present report, NASH would
also have been an important risk factor for both morbidity and
mortality.
In conclusion, as a result of the increased proportion of high-
risk patients undergoing major resection for malignancy, mor-
tality after liver resection is still far from zero. In order to
improve results after liver resection, it is important that more
conservative strategies that include parenchyma-sparing proce-
dures as well as oncological laparoscopic approaches continue to
be developed.
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